FDA advisory committee recommends (10-0) approval of CTL nineteen (tisagenlecleucel) CAR-T therapy, for the treatment of relapsed or refractory (r

Posted on July 10, 2017 by admin_en

Category: best car reviews 2017

, No Comments

FDA advisory committee recommends (10-0) approval of CTL nineteen (tisagenlecleucel) CAR-T therapy, for the treatment of relapsed or refractory (r/r) pediatric and youthful adult patients with B-cell acute lymphoblastic leukemia.-Novartis

one month ago on fourteen July two thousand seventeen

Data from Pharmawand – Curated by Toby Galbraith – Date added 14 July 2017